Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc bought 320,690 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average price of $11.49 per share, for a total transaction of $3,684,728.10. Following the transaction, the director now owns 16,040,851 shares in the company, valued at $184,309,377.99. This represents a 2.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Thursday, March 13th, Ecor1 Capital, Llc bought 468,356 shares of Zymeworks stock. The shares were acquired at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
- On Friday, January 17th, Ecor1 Capital, Llc bought 19,748 shares of Zymeworks stock. The shares were acquired at an average price of $13.87 per share, for a total transaction of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The shares were acquired at an average price of $14.01 per share, for a total transaction of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The shares were acquired at an average price of $13.39 per share, for a total transaction of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc purchased 204,098 shares of Zymeworks stock. The stock was purchased at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock. The stock was purchased at an average price of $14.07 per share, for a total transaction of $295,765.47.
- On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was purchased at an average price of $14.78 per share, for a total transaction of $2,333,466.40.
- On Monday, December 30th, Ecor1 Capital, Llc purchased 58,988 shares of Zymeworks stock. The stock was purchased at an average price of $14.47 per share, for a total transaction of $853,556.36.
- On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The stock was purchased at an average price of $14.12 per share, for a total transaction of $168,846.96.
- On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The stock was purchased at an average price of $14.38 per share, for a total transaction of $240,030.96.
Zymeworks Price Performance
NYSE:ZYME opened at $12.25 on Friday. The business has a fifty day simple moving average of $13.86 and a two-hundred day simple moving average of $13.66. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70. The company has a market capitalization of $852.32 million, a P/E ratio of -8.17 and a beta of 1.13.
Institutional Trading of Zymeworks
Analyst Upgrades and Downgrades
Several analysts have recently commented on ZYME shares. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a research note on Monday, December 16th. Citigroup increased their price objective on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Lifesci Capital started coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective for the company. Wells Fargo & Company increased their price objective on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. Finally, HC Wainwright increased their price objective on Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.
Read Our Latest Analysis on Zymeworks
About Zymeworks
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Stories
- Five stocks we like better than Zymeworks
- Breakout Stocks: What They Are and How to Identify Them
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Consumer Staples Stocks, Explained
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Invest in Biotech Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.